These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Glycoprotein C of herpes simplex virus type 1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells. Hidaka Y; Sakai Y; Toh Y; Mori R J Gen Virol; 1991 Apr; 72 ( Pt 4)():915-21. PubMed ID: 1849974 [TBL] [Abstract][Full Text] [Related]
46. Glycoprotein C of herpes simplex virus 1 acts as a receptor for the C3b complement component on infected cells. Friedman HM; Cohen GH; Eisenberg RJ; Seidel CA; Cines DB Nature; 1984 Jun 14-20; 309(5969):633-5. PubMed ID: 6328323 [TBL] [Abstract][Full Text] [Related]
47. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Sullivan BL; Takefman DM; Spear GT Virology; 1998 Sep; 248(2):173-81. PubMed ID: 9721226 [TBL] [Abstract][Full Text] [Related]
48. Factors influencing the interaction of herpes simplex virus glycoprotein C with the third component of complement. Huemer HP; Larcher C; Dierich MP; Falke D Arch Virol; 1992; 127(1-4):291-303. PubMed ID: 1333754 [TBL] [Abstract][Full Text] [Related]
49. Viral interference with antibody and complement. Lubinski J; Nagashunmugam T; Friedman HM Semin Cell Dev Biol; 1998 Jun; 9(3):329-37. PubMed ID: 9665870 [TBL] [Abstract][Full Text] [Related]
50. Binding of complement component C3b to glycoprotein gC of herpes simplex virus type 1: mapping of gC-binding sites and demonstration of conserved C3b binding in low-passage clinical isolates. Friedman HM; Glorioso JC; Cohen GH; Hastings JC; Harris SL; Eisenberg RJ J Virol; 1986 Nov; 60(2):470-5. PubMed ID: 3021981 [TBL] [Abstract][Full Text] [Related]
51. Structure-function analysis of herpes simplex virus glycoprotein B with fusion-from-without activity. Roller DG; Dollery SJ; Doyle JL; Nicola AV Virology; 2008 Dec; 382(2):207-16. PubMed ID: 18950828 [TBL] [Abstract][Full Text] [Related]
52. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Brown JS; Hussell T; Gilliland SM; Holden DW; Paton JC; Ehrenstein MR; Walport MJ; Botto M Proc Natl Acad Sci U S A; 2002 Dec; 99(26):16969-74. PubMed ID: 12477926 [TBL] [Abstract][Full Text] [Related]
53. Herpes simplex virus glycoprotein C is a receptor for complement component iC3b. Tal-Singer R; Seidel-Dugan C; Fries L; Huemer HP; Eisenberg RJ; Cohen GH; Friedman HM J Infect Dis; 1991 Oct; 164(4):750-3. PubMed ID: 1654359 [TBL] [Abstract][Full Text] [Related]
54. A novel function of the herpes simplex virus type 1 Fc receptor: participation in bipolar bridging of antiviral immunoglobulin G. Frank I; Friedman HM J Virol; 1989 Nov; 63(11):4479-88. PubMed ID: 2552134 [TBL] [Abstract][Full Text] [Related]
55. Inhibition of the alternative pathway of complement activation by a serum factor generated during transplant rejection. Spitzer R; Stitzel A; Florio L; Urmson J Immunochemistry; 1976 May; 13(5):395-400. PubMed ID: 780264 [No Abstract] [Full Text] [Related]
56. Complement-mediated bactericidal system: evidence for a new pathway of complement action. Moreau SC; Skarnes RC Science; 1975 Oct; 190(4211):278-80. PubMed ID: 1101380 [TBL] [Abstract][Full Text] [Related]
57. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report. Hetland G; Bungum L APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254 [TBL] [Abstract][Full Text] [Related]
58. The herpes simplex virus 1 IgG fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. Lubinski JM; Lazear HM; Awasthi S; Wang F; Friedman HM J Virol; 2011 Apr; 85(7):3239-49. PubMed ID: 21228231 [TBL] [Abstract][Full Text] [Related]
59. Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants. Bishop GA; Marlin SD; Schwartz SA; Glorioso JC J Immunol; 1984 Oct; 133(4):2206-14. PubMed ID: 6206157 [TBL] [Abstract][Full Text] [Related]